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The identification of distinct molecular subtypes of breast cancer has advanced the understanding 
and treatment of breast cancer by providing insight into prognosis, patterns of recurrence, and 
effectiveness of therapy. The prognostic significance of molecular phenotype with regard to 
distant recurrences and overall survival are well established in the literature and has been readily 
incorporated into systemic therapy management decisions. However, despite the accumulating 
data suggesting similar prognostic significance for locoregional recurrence, integration of 
molecular phenotype into local management decision making has lagged. Although there are 
some conflicting reports, collectively the literature supports a low risk of local recurrence (LR) in 
the hormone receptor (HR) positive luminal subtypes compared to HR negative subtypes [triple 
negative (TN) and HER2-enriched]. The development of targeted therapies, such as trastuzumab 
for the treatment of HER2-enriched subtype, has been shown to mitigate the increased risk of 
LR. Unfortunately, no such remedy exists to address the increased risk of LR for patients with 
TN tumors, making it a clinical challenge for radiation oncologists. In this review we discuss the 
correlation between molecular subtype and LR following either breast conservation therapy or 
mastectomy. We also explore the possible mechanisms for increased LR in TN breast cancer 
and radiotherapeutic implications for this population, such as the safety of breast conservation, 
consideration of dose escalation, and the appropriateness of accelerated partial breast irradiation.
Keywords: breast, cancer, subtype, local, recurrence, triple, negative, radiotherapy
those that were ER-positive and respond to antiestrogens and those 
that are ER-negative and are refractory to hormonal manipulation 
(Fisher et al., 1983). Another biologically distinct subset of breast 
cancer was discovered by novel work investigating the amplifica-
tion of the human epidermal growth factor receptor 2 (HER2/
neu) oncogene in breast cancer (Slamon et al., 1987). The analysis 
of 189 primary breast tumors showed that the amplification of 
the HER2/neu oncogene occurred in 25–30% of the specimens 
and that this genomic alteration predicted poor clinical outcome, 
even after adjustment for other prognostic variables. Similar to the 
earlier breakthrough investigations of hormone receptors (HR) 
in breast cancer, this finding led to the development of targeted 
therapy and has had a significant impact on the outcome of women 
with HER2 overexpressing tumors (Piccart-Gebhart et al., 2005; 
Romond et al., 2005).
Gene expression profiling, which examines the relative expres-
sion of thousands of genes in a single sample simultaneously, led to 
the discovery of distinct molecular subtypes within breast cancer 
(Perou et al., 2000). These molecular subtypes have phenotypic 
diversity with regard to multiple clinical outcomes, including 
response to chemotherapy, disease-free survival, and overall sur-
vival. Multiple datasets have confirmed these molecular breast 
cancer subtypes which include at least two luminal subtypes (lumi-
nal A and B) that comprise most ER-positive breast cancer and 
are characterized by a high expression of HR-related genes; the 
basal-like subtype, which is characterized by a high expression of a 
unique “basal” signature that includes genes common to the breast 
IntroductIon
Accurately estimating risk of local recurrence (LR) is essential to 
the practice of radiation oncology. In breast cancer, clinical and 
histopathologic risk factors for LR have been extensively studied 
and well-established. They include: margin status, young age, 
lymph node status, tumor size, lymphovascular invasion (LVI), 
and histologic grade (Clarke and Martinez, 1992). Computerized 
nomograms that calculate the risk of LR and aid local manage-
ment decision making exist (IBTR!, 2011). However, our ability to 
accurately estimate LR risk remains limited reflecting the hetero-
geneity of the disease. Over the past decade, molecular profiling 
has improved our understanding of how each tumor is unique 
and should be treated accordingly. Individualized care, based on 
a tumor’s genetic fingerprint (or surrogate subtype based on phe-
notypic markers) may 1 day govern adjuvant treatment decision 
making by identifying patients who are candidates for observation 
after breast conserving surgery, hypofractionation, accelerated par-
tial breast irradiation (APBI), or dose escalation.
Molecular phenotypIng In breast cancer
The first molecular distinction made in breast cancer was from 
the work in the 1960s and 1970s that identified and characterized 
estrogen receptor (ER) and progesterone receptor (PR) expression 
on breast cancer cells. This discovery quickly led to the develop-
ment of antiestrogen therapies. Responsiveness of the tumor to 
hormonal therapy correlated directly with receptor expression and 
identified an important biological subdivision within breast cancer: 
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PAM50 assay, which can measure a set of 50 intrinsic genes from 
formalin fixed, paraffin-embedded tissue, will permit additional 
molecular subtyping in archival specimens (Parker et al., 2009).
A large population-based study using the IHC surrogate mark-
ers for molecular subtype examined the association of molecular 
subtype with clinical characteristics and found that the luminal 
A, luminal B, basal-like, and HER2-enriched subtypes differed 
significantly by age, race, menopausal status, lymph node involve-
ment, histology group, tumor grade, and mitotic index (Carey 
et al., 2006). The most striking distribution was the overrepre-
sentation of basal-like tumors in premenopausal black women 
(39% in premenopausal black women vs. 14% in postmenopausal 
black women and 16% in non-black women of all ages, p < 0.001). 
Subsequent studies have confirmed that basal-like tumors are more 
frequent in younger patients and black women (Bauer et al., 2007; 
Millikan et al., 2008). In addition patients with basal-like tumors 
tended to have aggressive features including high nuclear grade, 
high mitotic index, and unfavorable histology (meta-plastic, ana-
plastic, or undifferentiated high grade carcinomas). Paradoxically, 
this subtype was not associated with higher regional lymph node 
involvement. More recent analyses have provided supporting evi-
dence for the decreased prevalence of lymph node metastasis in 
basal-like tumors and have shown a disconnect between tumors 
size and positive lymph nodes in this subtype (Crabb et al., 2008; 
Foulkes et al., 2009; Billar et al., 2010). This finding suggests a 
difference in mechanism of metastasis between luminal and basal 
tumors and highlights that these breast cancer molecular subtypes 
are distinct biological entities.
In addition to molecular subtypes developed through unsu-
pervised hierarchical clustering algorithms, several other tailored 
molecular assays have been developed to specifically guide the use 
of adjuvant systemic therapy including the 21-gene recurrence score 
assay (Oncotype DX, Genomic Health, Redwood City, CA, USA; 
REF #43 PAIK-NEED TO REORDER), the 70-gene recurrence score 
assay (MammaPrint, Agendia, Amsterdam, The Netherlands; van’t 
Veer et al., 2002), and several others. These assays will likely further 
supplement molecular phenotype and our appreciation of the het-
erogeneous behavior of breast cancer.
Molecular phenotype and local recurrence
The prognostic significance of molecular phenotype with regard to 
distant recurrences and overall survival are well established in the 
literature and has been readily incorporated into systemic therapy 
management decisions. However, despite the accumulating data 
suggesting similar prognostic significance for LR, integration of 
molecular phenotype into local management decision making has 
lagged. This may reflect some uncertainty regarding the correlation 
between LR risk and molecular phenotype as some of the earlier 
reports did not show a difference in LR by molecular phenotype 
(Haffty et al., 2006; Dent et al., 2007).
The first of these reports was a retrospective analysis of 482 
women treated with breast conservation therapy (BCT) at Yale 
between 1980 and 2003 for which ER, PR, and HER2 data were 
available (Haffty et al., 2006). With a median follow-up of 7.9 years, 
they reported 17% LR rates in the triple negative (TN) and non-TN 
cohorts. However, they also reported a difference in nodal relapse-
free survival of 94% in the TN cohort and 99% in the non-TN 
 myoepithelium, high expression of proliferation genes, and low 
expression of the ER signature and HER2 signatures; and the HER2-
enriched subtype, which is typified by high expression of HER2-
related and proliferation genes and low expression of HR-related 
genes. A fifth subtype, the normal breast subtype, has expression 
patterns similar to nonmalignant tissue and likely reflects sampling 
artifact (Sorlie et al., 2001, 2003; Sotiriou et al., 2003).
Molecular subtype has been shown to be significantly associ-
ated with differences in overall and relapse-free survival (Sorlie 
et al., 2001). The basal-like and HER2-enriched subtypes showed 
the poorest prognosis with shorter time to progression and lower 
overall survival. Patients belonging to the luminal A subtype had 
a considerably better prognosis compared with all groups, and 
those with the luminal B subtype had an intermediate outcome. 
The luminal subtypes are the most heterogeneous with regard to 
biology and outcomes (Perou et al., 2000; Sorlie et al., 2001, 2003; 
Sotiriou et al., 2003). Luminal A tumors have variable proliferation 
gene expression and also have highly variable prognostic signatures 
(Fan et al., 2006). Luminal B tumors, although still expressing the 
HR-related gene signature, do so at a lower level, have variable 
expression of the HER2 signature, and are generally more prolif-
erative than the luminal A subtype. In multiple datasets, patients 
with luminal B tumors have worse outcome compared luminal A 
tumors, despite both usually being ER-positive.
Because of the technical limitations of performing microarray 
expression analysis on formalin fixed, paraffin-embedded tissue, 
the use of ER, PR, HER2, and cytokeratin (CK) immunohisto-
chemical (IHC) markers has been used as a surrogate to molecular 
subtypes. The marker combinations that best matched the molecu-
lar profiles segregated the tumors into four groups (Table 1): (1) 
ER+ and/or PR+, HER2− for luminal A subtype; (2) ER+ and /or 
PR+, HER2+ for luminal B subtype (although this is known to 
misclassify a significant portion); (3) ER−, PR−, HER2−, CK 5/6+, 
and/or epidermal growth factor receptor (EGFR)+ for basal-like 
subtype; and (4) ER−, PR−, and HER2+ for the HER2-enriched 
subtype (Nielsen et al., 2004; Carey et al., 2006). The limitation 
of this simplification is that the prognostic power of the subtypes 
is based on a complex gene expression signature and that these 
molecular profiles are only associated with these IHC markers and 
not synonymous. In fact, the molecular profiles have been found to 
have a more robust predictive value compared with the surrogate 
markers (Sorlie, 2004). However, the proxy use of the IHC markers 
has allowed for the analysis of large datasets and the discovery of 
important aspects of the biology of these tumor subtypes. In the 
future, it is possible that RT-PCR-based approaches, such as the 
Table 1 | Immunohistochemically defined breast cancer molecular 
subtypes.
 ER PR HER2
Luminal A ER (+) and/or PR (+)  (−)
Luminal B ER (+) and/or PR (+)  (+)
HER2-enriched (−) (−) (+)
Triple negative (−) (−) (−)
ER, estrogen receptor; PR, progesterone receptor.
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Millar et al. (2009) corroborated these results with a prospective 
database review of 498 patients treated with BCT. With 84 months 
of follow-up, they reported LRR rates of 5.1% for luminal A, 8.7% 
for luminal B, 17.3% for basal, 15.4% for HER2-enriched, and 
12.5% for unclassified (p = 0.012). However, the rates of ipsilateral 
breast tumor recurrence (IBTR) were not statistically different by 
subtype. This study was unique because it used EGFR and CK 5/6 
status in addition to the standard ER, PR, and HER2 receptors to 
approximate the basal-like molecular subtype with a specificity of 
100% and a sensitivity of 76% (Cheang et al., 2008). This distinction 
separated the TN subtype into basal (EGFR+ and/or CK5/6+) and 
unclassified (negative for both EGFR and CK5/6).
Voduc et al. (2010) used a similar biomarker panel with the 
addition of Ki-67 and reported similar results with a series of 2,985 
women treated between 1986 and 1992 in British Columbia. With 
median follow-up of 12 years, they showed the greatest difference by 
molecular subtype in LR (8% luminal A, 21% HER2-enriched and 
14% basal-like) and regional recurrence (RR; 3% luminal A, 16% 
HER2-enriched and 14% basal-like). This pattern was also main-
tained among the patients treated with mastectomy. Importantly, 
patients with positive surgical margins were excluded from the 
analysis, which likely resulted in reduced overall LR rates com-
pared to other reports. A notable finding of this study was that the 
LRR rate of the TN-unclassified subtype was similar to that of the 
luminal subtypes and thus, the EGFR and CK5/6 markers appear to 
aid in determining which TNs are higher risk of LRR. TN tumors 
with high Ki-67 were also found to have an increased rate of LRR.
Billar et al. (2010) reported a retrospective review of 1,061 cases 
treated at the Mayo Clinic in Arizona between 2000 and 2008. With 
only 31 months of median follow-up, they showed a difference in 
LRR between the molecular phenotypes: 1% for the luminal A, 2.9% 
for the HER2-positive tumors (luminal B and HER2-enriched), 
and 5.7% for the TNs (p = 0.001).
The difference in LR among the molecular subtypes also extends 
to the postmastectomy and postmastectomy radiation (PMRT) 
setting. A reanalysis of the Danish Breast Cancer Group (DBCG) 
PMRT (trials 82b and 82c) data by molecular phenotype showed 
increased LRR among the HER2-enriched and TN phenotypes 
(Kyndi et al., 2008). For the patients treated with mastectomy and 
PMRT, 15 year LRR rates were 3% for luminal A, 3% for luminal 
B, 21% for HER2-enriched, and 15% for TN.
A point of contention around these reports is that due to their 
retrospective design, the authors could not control for confound-
ing factors such as systemic therapy. As expected, the HR nega-
tive subtypes were more likely to receive chemotherapy (Nguyen 
et al., 2008). An effort to address this issue was made by Albert 
et al. (2010) by limiting their analysis to tumors <1 cm because 
such small tumors were less likely to be treated with chemotherapy 
(only 8% of their total cohort). Their series included 911 patients 
treated at MD Anderson Cancer Center between 1997 and 2002. 
With a median follow-up of 6 years, they showed statistically signifi-
cant difference in LRR by receptor status for ER [ER(−) 10.6% vs. 
ER(+) 4.2%, p = 0.016], PR [PR(−) 9% vs. PR(+) 4.2%, p = 0.009], 
and HER2 [HER2(+) 17.5% vs. HER2(−) 3.9%, p = 0.009]. The 
authors also analyzed LRR by combined HR and HER2 status. 
Eight year LRR rates were: 3.5% for HR+HER2− (luminal A), 
5.8% for HR−HER2− (TN), 13.4% for HR+HER2+ (luminal B), 
cohort (p = 0.05). This study reports relatively high rates of LR, 
which likely reflects the less aggressive systemic therapy typically 
used in patients in the early portion of the study period. In addition, 
this higher recurrence rate could also reflect a bias during the earlier 
portion of the study period to obtain IHC markers more often in 
women with higher risk tumors. This selection bias also explains 
the relatively high rate of TN tumors included in the study (25% 
of the cohort). Another limitation of this study is that HER2 IHC 
stain was not confirmed with FISH, which is known to contribute 
to misclassification. Finally, the TNs were compared to all non-TNs 
as opposed to each molecular phenotype compared individually. 
The non-TN cohort LR rate was elevated by the inclusion of the 
HER2-enriched subtype that has been consistently shown to have 
a higher rate of LR in the pre-trastuzumab era (Nguyen et al., 2008; 
Millar et al., 2009; Voduc et al., 2010).
The second report that did not show a difference in LR by molec-
ular phenotype was reported by Dent et al. (2007). This report 
was a database review of 1,601 women with invasive breast cancer 
with known ER, PR, and HER2 status treated between 1987 and 
1997 at the Henrietta Banting Breast Cancer Centre. The majority 
of the subjects included in this analysis had palpable tumors and 
nearly half of the patients had positive lymph nodes. The analysis 
also included patients treated with mastectomy. With a median 
follow-up of 8.1 years, they reported no statistically significant dif-
ference in LR between the TN and non-TN (13 vs. 12% p = 0.77). 
Although they did not see a higher rate of LR, they did observe 
a shorter time to LR among the TN phenotype (2.8 vs. 4.2 years, 
p = 0.02). Similar to Haffty et al. (2006) this report was subject 
to misclassification as FISH analysis was not available to confirm 
HER2 amplification. They also had a relatively high overall LR rate 
which reflects the earlier time period as well as the more advanced 
stage of tumors included. The TN cohort also had bigger tumors 
(63.5% TN > 2 cm vs. 37.4% of non-TN, p < 0.0001) and higher 
rates of positive lymph nodes (54.4% of TN vs. 45.6% of non-
TN, p = 0.02) and thus were potentially more likely to be treated 
with mastectomy and chemotherapy, which could confound the 
comparison of LR.
Another retrospective database review of 753 T1–2 breast can-
cers treated with BCT at Fox Chase Cancer Center also did not show 
a difference in isolated locoregional recurrence (LRR) at 5 years by 
molecular phenotype (Freedman et al., 2009). However, the total 
LRR [including LR with synchronous distant metastases (DM)] was 
higher among the TN subtype (5.3%) compared to the HR positive 
cohort (2.6%), p = 0.05. This report highlights the fact that DM is a 
major competing risk for the TN subtype and may artificially lower 
the LR rates in studies that routinely only document first site of 
recurrence. Similar to Dent et al. (2007), the authors also reported 
a shorter time to LR among the TN subtype.
In contrast to these reports, there is mounting evidence that 
molecular phenotype is prognostic for LR risk. Nguyen et al. (2008) 
published a retrospective review of 793 consecutive patients with 
invasive breast cancer treated with BCT from 1998 to 2001. With 
a median follow-up of 70 months, they reported 5-year LR rate of 
0.8% for luminal A, 1.5% for luminal B, 8.4% for HER2-enriched, 
and 7.1% for TN. On multivariate analysis, HER2-enriched 
[adjusted hazard ratio (AHR) = 9.2, p = 0.012] and TN (AHR = 7.1, 
p = 0.009) subtypes were associated with increased LR.
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neu  receptor, is the obvious answer for the HER2-enriched sub-
type as it has been shown to decrease LRR in HER2+ disease by 
approximately 50% in randomized trials (Piccart-Gebhart et al., 
2005; Romond et al., 2005). None of the HER2-enriched patients 
received trastuzumab in the studies that demonstrated increased 
risk of LRR among this subtype. However, the report by Billar et al. 
(2010), the only study that included patients who were treated with 
trastuzumab, showed a low rate of LRR among the HER2+ patients 
(2.9%). Thus, the addition of trastuzumab may eliminate or narrow 
the difference in LR rates for the HER2+ subtypes. Unfortunately, 
no such remedy exists to address the increased risk of LRR among 
the TN subtype, making it a clinical challenge for surgical and 
radiation oncologists.
Before postulating how we may be able to alter our practices to 
address the increased risk of LRR in TN breast cancer (TNBC), it 
is important to understand what may be the underlying potential 
mechanism of the increased risk of LRR. Existing theories include: 
and 29.2% for the HR−HER2+ (HER2-enriched; p = 0.014). On 
multivariate analysis, ER/PR-negative and HER2-positive status 
independently predicted for LRR. The authors also ran multivariate 
analysis after excluding the 61 patients who received chemotherapy 
and ER/PR-negative status still maintained statistically significant 
correlation with LRR (p = 0.005). Although this study is compel-
ling, the need for prospective randomized trials to validate these 
findings remains.
radIotherapeutIc IMplIcatIon of Molecular 
phenotype
Although there are some conflicting reports, collectively the lit-
erature supports a low risk of LRR in the luminal phenotypes and 
increased risk of LRR in TN and HER2-enriched breast cancer 
phenotypes after BCT and mastectomy with PMRT (summarized 
in Table 2). This begs the question, what can be done to com-
bat this risk? Trastuzumab, a monoclonal antibody to the HER2/
Table 2 | Summary of literature exploring the relationship of local recurrence rate and breast cancer molecular subtype.
Author n Median follow-up (years) Local recurrence rate (%) p-value
Haffty et al. (2006) 482 7.9 Non-TN: 17 0.823
   TN: 17 
Dent et al. (2007) 1,601 8.1 Non-TN: 12 0.77
   TN: 13 
Nguyen et al. (2008) 793 5.8 Luminal A: 1.8 SS**
   Luminal B: 1.5 
   HER2: 8.4 
   Basal/TN: 7.1 
Freedman et al. (2009) 753 3.4–4 Luminal: 2.6† 0.05
   TN: 5.3† 
Millar et al. (2009) 498 7 Luminal A: 5.1* 0.012
   Luminal B: 8.7* 
   HER2-enriched: 15.4* 
   Basal-like: 17.3* 
   Unclassified: 12.5* 
Voduc et al. (2010) 2,985 12 Luminal A: 8 0.005
   Luminal B: 10 
   Luminal-HER2: 9 
   HER2- enriched: 21 
   Basal-like: 14 
   TNP non-basal: 8 
Billar et al. (2010) 1,061 2.6 Luminal A: 1* 0.001
   Luminal B and HER2-enriched: 2.9* 
   TN: 5.7* 
Albert et al. (2010) 911 6 Luminal A: 3.5* 0.014
   Luminal B: 13.4* 
   HER2-enriched: 29.2* 
   TN: 5.8* 
Kyndi et al. (2008) 1,000 17 Luminal A: 3‡ SS**
   Luminal B: 3‡ 
   HER2-enriched: 21‡ 
   TN: 15‡ 
*Isolated locoregional recurrence (LRR) rate, †total LRR (including LRR with synchronous distant metastasis), ‡LRR after mastectomy and PMRT, **stastistically 
significant (SS) differences between groups without p-value reported.
TN, triple negative; TNP, triple negative phenotype; SS, statistically significant; PMRT, postmastectomy radiation.
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In Kyndi’s study, the distant recurrence and overall survival 
rates among the TN phenotype was also comparable to the lumi-
nal phenotypes which is not consistent with other reports in the 
literature. This discrepancy could be a result of heterogeneity within 
TNs. For example, the Danish cohort of TNs likely represent fewer 
women of African descent and there is evidence that Caucasian 
(especially postmenopausal Caucasian) women may have better 
outcomes compared to women of African descent (Sachdev et al., 
2010). Although this difference could represent differences in socio-
economic status and access to care, it could also be explained by 
differences in biology.
2-Is the poor prognosIs assocIated wIth tnbc 
transIent?
The difference in LRR between the subtypes is most dramatic in the 
first few years of follow-up. Dent et al. (2007) showed that nearly 
all TN failures occur within the first 5 years, while the failure rate 
among the luminal subtypes continues with time. Thus, Dent et al. 
(2007) concluded that longer follow-up diminishes the difference 
in outcomes among the subtypes and that the poor prognosis of 
TNs is merely transient. However, longer follow-up does not elimi-
nate the difference entirely as shown by Voduc et al. (2010) who 
reported statistically significant difference in LRR with a mature 
median follow-up of 12 years. The prolonged course of LR in lumi-
nal subtypes may reflect adjuvant hormonal therapy keeping LR 
dormant for many years and/or more indolent biology while the 
accelerated course of LR in TNBC may reflect the high prolifera-
tive genetic signature of the basal-like subtype (Sorlie et al., 2001). 
For this reason, accelerated hyperfractionated radiotherapy may 
be beneficial for the treatment of TNBC. This method of radia-
tion therapy typically uses slightly smaller dose per fraction, but 
delivers more than 5 treatments per week. For example delivering 
1.5 Gy per fraction 10 times per week with treatments delivered 
twice daily for five consecutive days. This would yield a weekly dose 
is 15 Gy, which is 50% more dose than the weekly dose of 10 Gy 
given with standard fractionation of 2 Gy per fraction given for 5 
consecutive days. Therefore, with accelerated hyperfractionation, 
the total radiation course could be completed over a shorter period 
of time, which minimizes the effect of ongoing tumor proliferation 
that occurs during treatment. This could improve local control in 
a tumor subtype with very rapid proliferation such as the TNBC, 
and should be considered as part of a prospective clinical trial for 
women with this molecular subtype.
3-tnbc has a hIgher rate of resIdual dIsease after 
luMpectoMy
TNBC is more common in younger women who may have smaller, 
more cosmetically driven surgeries as well as denser breasts that may 
harbor mammographically occult disease leading to an increased 
residual disease burden following lumpectomy (Tyler et al., 1995; 
Marin-Gutzke and Sanchez-Olaso, 2010; Pinsky and Helvie, 2010). 
This may result in increased residual disease after lumpectomy and 
subsequent increased risk of LR. To address this hypothesis we per-
formed a retrospective pathologic chart review that revealed that 
TNBC are at increased risk of having residual disease after lumpec-
tomy. We obtained pathologic data from nearly 400 women who 
had a lumpectomy for invasive cancer followed by a re-excision (or 
(1) TNBC is radioresistant, (2) TNBC has a higher proliferative rate 
resulting in early failures, but with longer follow-up the luminal 
subtypes “catch up,” (3) TNBC has an increased rate of residual 
disease after lumpectomy.
1-Is tnbc radIoresIstant?
The impact of molecular phenotype on the response to radiation 
was recently reported by a retrospective subset analysis of data from 
1,000 patients enrolled in the Danish PMRT trials DBCG 82b and 
c (Kyndi et al., 2008). The patients had clinical features associated 
with an increased risk of LR following mastectomy including large 
primary tumors (>5cm), invasion of skin or pectoralis fascia, or 
lymph node involvement. The premenopausal women (DBCG 82b) 
were treated with adjuvant cyclophosphamide, methotrexate, fluo-
rouracil (CMF) chemotherapy while the postmenopausal women 
(DBCG 82c) received tamoxifen. All women were randomized to 
either receive or not receive PMRT. There was an overall survival 
benefit with PMRT in both the pre- and postmenopausal women 
(Overgaard et al., 1997, 1999). ER, PR, and HER2 status were not 
known at the time of the DBCG initial report and thus, Kyndi et al. 
(2008) retrospectively performed tissue microarray analysis for 
these receptors in order to analyze outcomes by molecular subtype. 
Of note, HER2 2+ IHC pattern on microarray was confirmed for 
gene amplification by FISH analysis. They found that the luminal 
A, luminal B, and TN subtypes had a statistically significant LRR 
benefit with PMRT, but only the luminal A subtype had a statisti-
cally significant overall survival benefit. The authors also noted that 
the TN subtype had a smaller proportional locoregional control 
benefit compared to the luminal A and luminal B subtype and 
concluded that increased radioresistance among the HR negative 
subtypes may explain, in part, the lack of improvement in survival.
However, this study did not have the statistical power to detect 
significant survival benefit from PMRT in the non-luminal A 
cohorts that had significantly fewer number of patients. In addi-
tion to lack of statistical power, another explanation for the lack 
of survival benefit among the TN subtype was the use of subopti-
mal systemic therapy. The women enrolled on these trials were at 
high risk for harboring micrometastases at time of diagnosis and 
thus systemic therapy is integral toward maximizing survival. The 
premenopausal women only received CMF chemotherapy which 
is now considered suboptimal systemic therapy for this high risk 
breast cancer population. The postmenopausal women received 
tamoxifen alone which is ineffective in TNBC. In addition, many 
studies have shown that TN subtype has a predilection for distant 
failure (Sorlie et al., 2001). As the risk of distant failure increases, 
locoregional control becomes less likely to translate into survival 
benefit. This theory is corroborated by a separate subgroup analysis 
by DBCG analyzing the same data based on good, intermediate, 
and high risk groups. They found that the largest translation of 
LRR benefit from PMRT to survival benefit was seen in the “good” 
prognosis group (Kyndi et al., 2009). This was despite the fact that 
the high risk group had a larger proportional LR benefit with PMRT. 
TNBC had a clear reduction of LRR with PMRT (p = 0.001) in 
these trials, but this improvement in local control very likely did 
not translate to a survival benefit because of the competing risk 
of distant failure in the setting of suboptimally treated advanced 
stage disease.
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The finding that TNBCs harbor more microscopic residual disease 
after lumpectomy suggests that these patients may benefit from dose 
escalation. The European Organization for Research and Treatment 
for Cancer (EORTC) 22881 trial examined the benefit of tumor bed 
boost (defined as additional radiation dose delivered to the tumor 
bed) to BCT in over 5,000 women (Bartelink et al., 2007). With over 
10 years of follow-up, LR rates were 10.2% in the whole breast irra-
diation only arm and 6.2% in the boost arm (p < 0.0001) with a 
hazards ratio of 0.59. The statistically significant local control benefit 
of boost was maintained for all age groups although most dramatic 
in the younger age groups. Currently, the National Comprehensive 
Cancer Network (NCCN) recommends tumor bed boost for women 
at higher risk for recurrence including women <50 years old, posi-
tive axillary lymph nodes, close surgical margins, or LVI1. Subgroup 
analysis of the EORTC 22881 boost vs. no boost trial showed that the 
largest proportional benefit of boost was in the high grade tumors 
and in the patients under the age of 50 (Jones et al., 2009). Women 
with TNBC are more frequently young patients and overwhelmingly 
have high grade tumors. Therefore, the subgroups that were found 
to have a more robust local control benefit from tumor bed boost 
likely contained a higher proportion of TN disease.
Radiation oncologists should strongly consider tumor bed boost 
for TNBC to mitigate the increased risk of LR. Although TNBC is 
associated with an increased risk of residual disease after lumpec-
tomy, the risk of recurrence is still acceptably low to support breast 
conservation. Therefore, TNBC is not an indication for mastectomy.
apbI and Molecular phenotype
Accelerated partial breast irradiation is an alternative technique to 
standard whole breast irradiation. With APBI the radiation target 
is limited to the tissues surrounding the tumor bed and the dose is 
hypofractionated (fewer total number of fractions generally with 
larger dose per fraction) and delivered over an accelerated time 
course (generally 1 week). There is evolving data APBI studies 
demonstrating a correlation between local failure and molecular 
phenotype. NSABP B-39/RTOG 0413, a randomized trial com-
paring whole breast irradiation to APBI, has been slow to enroll 
ER-negative patients2. This is likely due to conservative bias among 
oncologists regarding concern for a higher risk of LR in patients with 
ER-negative disease. Currently, the American Society for Radiation 
Oncology (ASTRO) consensus guidelines designated ER-negative 
status a “cautionary” criteria for APBI and strongly encourages the 
enrollment of ER-negative patients in the trial (Smith et al., 2009).
The literature on APBI and breast cancer subtype is evolving and 
mixed. There are at least two reports that do not show any difference 
in LR after APBI by subtype. The first is a by Wilder et al. (2010) 
and is limited by short follow-up of only 22 months. They analyzed 
209 women treated with APBI and had excellent local control rates 
of 99–100% for all subtypes, indicating careful patient selection 
and short follow-up. However, a second report by Wilkinson et al. 
(2011) showed similar results with a mean of 4.1 years of follow-
up. They reported no LR in 20 TNBC patients treated with APBI. 
In contrast, Pashtan et al. (2010) reported on a series of 99 Stage I 
patients treated with APBI and found that patients with TN tumors 
mastectomy) within a 3-month period. Descriptive statistics of the 
cohort by molecular phenotype are shown in Table 3. On univariate 
analysis, age, tumor size, margin status, lymph node involvement, 
LVI, grade, multifocality, and molecular phenotype were all cor-
related with residual invasive disease (Table 4). On forward selec-
tion, step-wise multivariate analysis, only lymph node involvement, 
tumor size, and TN phenotype maintained statistical significance as 
independent predictors of residual invasive disease (Table 5).
Table 3 | Descriptive statistics by molecular phenotype in the 
retrospective pathologic chart review examining rate of residual 
disease after lumpectomy.
n = 345 Luminal A and HER2-enriched, Triple 
 B, n = 286 n = 16 negative, 
   n = 43
Residual disease (%) 29 24 50
Age (y) 59 57  50
Tumor size (cm) 1.5 1.2 1.6
Multifocal (%) 30 31 32
Node+(%) 32 27 40
Margin+(%) 33 32 28
EIC (%) 35 63 43
LVI (%) 20 19 30
High grade (%) 19 86 74
High mitotic count (%)  1 50 56
EIC, extensive intraductal component; LVI, lymphovascular invasion.
Table 4 | Univariate analysis relating risk factors associated with local 
recurrence risk with incidence of residual disease found in the 
re-excision specimen after lumpectomy.
Variable n OR (95% CI) p-Value
Triple negative 343 2.48 (1.30, 4.74) 0.006
Node + 345 3.69 (2.29, 5.97) <0.0001
Multifocal 367 1.78 (1.12, 2.85) 0.02
LVI+ 367 2.56 (1.53, 4.28) 0.0004
Age > 45 365 0.45 (0.27, 0.76) 0.003
Margins + 363 1.76 (1.12, 2.76) 0.01
High grade 346 2.14 (1.32, 3.47) 0.002
Tumor size 366 <1.0 cm: reference 0.0005
  1.1–2 cm: 3.00 (1.62, 5.54) <0.0001
  >2.0 cm: 5.70 (2.98–10.93) 
OR, odds ratio; LVI, lymphovascular invasion.
Table 5 | Multivariate analysis identifying independent risk factors for 
having residual disease found in the re-excision specimen after 
lumpectomy.
Variable OR (95% CI) p-Value
Nodal + 3.06 (1.77–5.30) <0.0001
TN status 3.28 (1.56–6.89) 0.002
Tumor size 3.49 (1.65–7.38) 0.001
OR, odds ratio; TN, triple negative.
1http://www.nccn.com/patient-guidelines.html#breast
2http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0413
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FISH; Stackievicz et al., 2010). Although the prognostic signifi-
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is still a viable marker that can be targeted with trastuzumab and 
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et al. (2011) reported on a phase II trial conducted at MDACC on 
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The prognostic significance of molecular phenotype in DCIS has 
also been studied. Zhou et al. (2010) reported results of a cohort study 
of 392 women with primary DCIS who had complete IHC data avail-
able for the ER, PR, HER2, EGFR, and CK 5/6 markers (Zhou et al., 
2010). Molecular phenotype was defined similar to the definitions 
used in invasive cancer. The 8.2% were basal-like DCIS (negative for 
ER, HER2 and positive for EGFR and/or CK 5/6), 89.5% were luminal 
or HER2+, and 2.3% were unclassified (negative for all markers). On 
univariate and multivariate analysis, with over 8 years of median 
follow-up, basal-like DCIS showed a higher risk of LR and invasive 
recurrence compared to non-basal-like DCIS but this result was not 
statistically significant (p = 0.08 and p = 0.15, respectively). Further 
studies evaluating molecular phenotype and DCIS are warranted.
conclusIon
Molecular profiling is an area of rapid growth in breast cancer 
research and will continue to evolve over time. Although the corre-
lation between molecular profiles and LRR are compelling, valida-
tion with larger independent datasets and prospective randomized 
trials are still necessary before we can make any definitive con-
clusions or make any major deviations from our current clinical 
practice. The studies reviewed in this paper should be considered 
hypothesis generating. Factoring molecular phenotype and recur-
rence scores into adjuvant treatment decision making, along with 
the traditional histopathologic and clinical risk factors, may be 
appropriate in select situations.
had a significantly higher rate of LR compared to other subtypes. 
With a median follow-up of 47.5 months, they had an overall 5 year 
actuarial LR rate of 6%. Three of the six LR occurred in TN patients, 
yielding a LR of 32.5% among TN patients compared to only 3% 
among the other subtypes (p = 0.0001). Interestingly, only one out 
of the six LR occurred in the same quadrant, and the other five 
were deemed elsewhere LR. In a report out of the University of 
Wisconsin, of 136 “cautionary” status patients treated with APBI, 
11 were ER-negative. After a median follow-up of 60 months, 
they reported a total of five IBTR. Two of the five IBTR were in 
ER-negative patients, yielding a failure rate of 18% in ER-negative 
patients compared to only 2.4% among the ER-positive patients 
(McHaffie et al., 2010). Additionally, ER-negative status was the 
only factor that correlated with IBTR after APBI in the 1,225 cases 
from the Mammosite® Registry (Beitsch et al., 2010).
luMInal subtype heterogeneIty and 21-gene 
recurrence score assay
In addition to the identification of molecular phenotypes in breast 
cancer, gene recurrence score assays are emerging and may be useful 
in predicting the risk of LR. One example is a 21-gene recurrence score 
assay (Oncotype DX, Genomic Health, Redwood City, CA, USA) that 
was developed through the prospective selection of genes that were 
thought to correlate with distant recurrence risk in node-negative, 
ER(+) breast cancer (Paik et al., 2004). Initially it was designed to be 
a prognostic tool to quantify the risk of distant recurrence. It was later 
found to also be predictive of the benefit of adjuvant chemotherapy 
as well as the risk of LR (Paik et al., 2006). Mamounas et al. (2010) 
reported a statistically significant association between recurrence 
score (RS) and LRR in the NSABP B-14 and B-20 datasets of 895 
patients. They found that 10-year LRR was 4.3% for patients with 
low RS (<18), 7.2% for intermediate risk RS (Haffty et al., 2006; Dent 
et al., 2007; Cheang et al., 2008; Crabb et al., 2008; Kyndi et al., 2008; 
Nguyen et al., 2008; Foulkes et al., 2009; Freedman et al., 2009; Millar 
et al., 2009; Albert et al., 2010; Billar et al., 2010; Voduc et al., 2010), 
and 15.8% for high RS (>30; p < 0.001). Thus, incorporating RS into 
local management decision making for luminal/ER(+) subtypes may 
be useful and can potentially help distinguish which patients with 
luminal breast cancer are at increased risk of LR.
dcIs and Molecular phenotype
The prognostic significance of molecular markers in ductal carci-
noma in situ (DCIS) has been an area of ongoing research. HER2 
expression has been found to correlate with aggressive histologic 
features (Cornfield et al., 2004; Stackievicz et al., 2010) such as 
high nuclear grade and comedo necrosis. However, unlike invasive 
breast cancer, the prognostic significance of HER2 expression in 
DCIS has not been demonstrated. Stackievicz et al. (2010) reported 3http://www.nsabp.pitt.edu/B43_Information.asp
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